image
Healthcare - Medical - Distribution - NYSE - US
$ 81.46
-1.68 %
$ 4.04 B
Market Cap
19.12
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one PBH stock under the worst case scenario is HIDDEN Compared to the current market price of 81.5 USD, Prestige Consumer Healthcare Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one PBH stock under the base case scenario is HIDDEN Compared to the current market price of 81.5 USD, Prestige Consumer Healthcare Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one PBH stock under the best case scenario is HIDDEN Compared to the current market price of 81.5 USD, Prestige Consumer Healthcare Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart PBH

image
$90.0$90.0$88.0$88.0$86.0$86.0$84.0$84.0$82.0$82.0$80.0$80.0$78.0$78.0$76.0$76.0$74.0$74.0$72.0$72.0$70.0$70.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
1.13 B REVENUE
-0.21%
342 M OPERATING INCOME
-0.88%
209 M NET INCOME
354.34%
249 M OPERATING CASH FLOW
8.36%
-20.1 M INVESTING CASH FLOW
-73.61%
-241 M FINANCING CASH FLOW
-29.69%
290 M REVENUE
2.39%
92 M OPERATING INCOME
9.04%
61 M NET INCOME
12.24%
65.1 M OPERATING CASH FLOW
-6.75%
-9.82 M INVESTING CASH FLOW
-384.26%
-53.9 M FINANCING CASH FLOW
-5.21%
Balance Sheet Prestige Consumer Healthcare Inc.
image
Current Assets 375 M
Cash & Short-Term Investments 46.5 M
Receivables 177 M
Other Current Assets 152 M
Non-Current Assets 2.94 B
Long-Term Investments 0
PP&E 89.3 M
Other Non-Current Assets 2.85 B
5.33 %4.57 %86.01 %Total Assets$3.3b
Current Liabilities 117 M
Accounts Payable 39 M
Short-Term Debt 6.15 M
Other Current Liabilities 71.9 M
Non-Current Liabilities 1.55 B
Long-Term Debt 1.13 B
Other Non-Current Liabilities 413 M
4.32 %68.15 %24.82 %Total Liabilities$1.7b
EFFICIENCY
Earnings Waterfall Prestige Consumer Healthcare Inc.
image
Revenue 1.13 B
Cost Of Revenue 501 M
Gross Profit 624 M
Operating Expenses 282 M
Operating Income 342 M
Other Expenses 133 M
Net Income 209 M
1b1b1b1b800m800m600m600m400m400m200m200m001b(501m)624m(282m)342m(133m)209mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
55.49% GROSS MARGIN
55.49%
30.43% OPERATING MARGIN
30.43%
18.60% NET MARGIN
18.60%
12.65% ROE
12.65%
6.31% ROA
6.31%
8.10% ROIC
8.10%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Prestige Consumer Healthcare Inc.
image
300m300m250m250m200m200m150m150m100m100m50m50m00201620162017201720182018201920192020202020212021202220222023202320242024
Net Income 209 M
Depreciation & Amortization 30.7 M
Capital Expenditures -9.55 M
Stock-Based Compensation 14 M
Change in Working Capital -39.8 M
Others -21.3 M
Free Cash Flow 239 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Prestige Consumer Healthcare Inc.
image
Wall Street analysts predict an average 1-year price target for PBH of $85.8 , with forecasts ranging from a low of $71 to a high of $93 .
PBH Lowest Price Target Wall Street Target
71 USD -12.84%
PBH Average Price Target Wall Street Target
85.8 USD 5.33%
PBH Highest Price Target Wall Street Target
93 USD 14.17%
Price
Max Price Target
Min Price Target
Average Price Target
95959090858580807575707065656060May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0.475 USD DIVIDEND PER SHARE
Q1
Q2
Q3
Q4
0.5000.5000.4500.4500.4000.4000.3500.3500.3000.3000.2500.2500.2000.2000.1500.1500.1000.1000.0500.0500.0000.0000.4750.4820182018
Download SVG
Download PNG
Download CSV
5. COMPETITION
slide 2 of 9
6. Ownership
Insider Ownership Prestige Consumer Healthcare Inc.
image
Sold
0-3 MONTHS
1.65 M USD 2
3-6 MONTHS
12 M USD 5
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Prestige Consumer Gains 17.1% in a Year: What's Driving the Stock? PBH's shares rise on the back of its portfolio of consumer brands and focus on core strategies to achieve long-term success. zacks.com - 3 weeks ago
Should You Consider Retaining PBH Stock in Your Portfolio Now? Investors remain optimistic about Prestige Consumer due to its strong focus on brand building and strategic acquisition. zacks.com - 3 weeks ago
Premium Brands Holdings Corporation Announces $150 Million Financing of Convertible Unsecured Subordinated Debentures NOT FOR DISTRIBUTION TO U.S. NEWS SERVICES OR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, March 05, 2025 (GLOBE NEWSWIRE) -- Premium Brands Holdings Corporation (“Premium Brands” or the “Company”) (TSX: PBH), a leading producer, marketer and distributor of branded specialty food products, is pleased to announce it has entered into an agreement with a syndicate of underwriters co-led by CIBC Capital Markets, National Bank Financial, BMO Capital Markets and Scotiabank (collectively, the “Underwriters”), pursuant to which the Company will issue on a “bought-deal” basis, subject to regulatory approval, $150,000,000 aggregate principal amount of convertible unsecured subordinated debentures (the “Debentures”) at a price of $1,000 per Debenture (the “Offering”). The Company has also granted the Underwriters an over-allotment option to purchase up to an additional $22,500,000 aggregate principal amount of Debentures, on the same terms, exercisable in whole or in part at any time for a period of up to 30 days following closing of the Offering, to cover over-allotments, if any. globenewswire.com - 1 month ago
PBH or BSX: Which Is the Better Value Stock Right Now? Investors interested in Medical - Products stocks are likely familiar with Prestige Consumer Healthcare (PBH) and Boston Scientific (BSX). But which of these two companies is the best option for those looking for undervalued stocks? zacks.com - 2 months ago
PBH Q3 Earnings Beat Estimates, EPS View Raised, Shares Gain 14.8% Prestige Consumer Healthcare witnesses continued international growth in the third quarter, banking on strong sales of the Hydralyte brand. zacks.com - 2 months ago
Prestige Consumer Healthcare Inc. (PBH) Q3 2025 Earnings Call Transcript Prestige Consumer Healthcare Inc. (NYSE:PBH ) Q3 2025 Results Conference Call February 6, 2025 8:30 AM ET Company Participants Phil Terpolilli - Vice President, Investor Relations Ron Lombardi - Chairman, President & Chief Executive Officer Christine Sacco - Chief Financial Officer Conference Call Participants Rupesh Parikh - Oppenheimer & Company Susan Anderson - Canaccord Genuity Keith Devas - Jefferies David Shakno - William Blair Linda Bolton Weiser - D. A. Davidson Anthony Lebiedzinski - Sidoti & Company Operator Thank you for standing by, and welcome to Prestige Consumer Healthcare's Third Quarter 2025 Earnings Conference Call. seekingalpha.com - 2 months ago
Prestige Consumer Healthcare (PBH) Q3 Earnings and Revenues Beat Estimates Prestige Consumer Healthcare (PBH) came out with quarterly earnings of $1.22 per share, beating the Zacks Consensus Estimate of $1.16 per share. This compares to earnings of $1.06 per share a year ago. zacks.com - 2 months ago
Prestige Consumer Healthcare Inc. Reports Record Third Quarter Results and Raises Full-Year Earnings Outlook TARRYTOWN, N.Y., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its third quarter and first nine months ended December 31, 2024. globenewswire.com - 2 months ago
PBH vs. BSX: Which Stock Is the Better Value Option? Investors looking for stocks in the Medical - Products sector might want to consider either Prestige Consumer Healthcare (PBH) or Boston Scientific (BSX). But which of these two stocks presents investors with the better value opportunity right now? zacks.com - 2 months ago
Prestige Consumer Stock Up 29.9% in a Year: What's Behind the Surge? PBH sees remarkable gains from long-term brand-building strategies and developing the e-commerce channel. zacks.com - 2 months ago
PBH or BSX: Which Is the Better Value Stock Right Now? Investors interested in stocks from the Medical - Products sector have probably already heard of Prestige Consumer Healthcare (PBH) and Boston Scientific (BSX). But which of these two stocks offers value investors a better bang for their buck right now? zacks.com - 3 months ago
PBH vs. BSX: Which Stock Is the Better Value Option? Investors looking for stocks in the Medical - Products sector might want to consider either Prestige Consumer Healthcare (PBH) or Boston Scientific (BSX). But which of these two stocks presents investors with the better value opportunity right now? zacks.com - 3 months ago
8. Profile Summary

Prestige Consumer Healthcare Inc. PBH

image
COUNTRY US
INDUSTRY Medical - Distribution
MARKET CAP $ 4.04 B
Dividend Yield 0.00%
Description Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.
Contact 660 White Plains Road, Tarrytown, NY, 10591 https://www.prestigebrands.com
IPO Date Feb. 10, 2005
Employees 570
Officers Mr. Adel Mekhail Executive Vice President of Marketing & Sales Ms. Christine Sacco CPA Chief Financial Officer & Chief Operating Officer Mr. William C. P'Pool J.D. Senior Vice President, General Counsel & Corporate Secretary Mr. Philip David Terpolilli C.F.A. Director of Investor Relations Dean Siegal Director of Communications Ms. Mary Beth Fritz Senior Vice President of Quality & Regulatory Affairs Mr. Jeffrey Zerillo Senior Vice President of Operations